This webinar covered
To conclude this landscape review series, this complimentary webinar with the Beacon DDR team provided additional analysis on the reports and offered an opportunity to ask any questions about the data.
This webinar uncovered further analysis of:
- The Clinical Trial Landscape – A 2022 recap and the key developments made over the past year, top disease indications, non-PARP targets and combination trials.
- The Drug Landscape – The current drug landscape with a focus on PARP1-selective and cell cycle checkpoint assets, repair pathways, targets and more.